EXAS חוב כולל להון Exact Sciences Corporation

Exact Sciences is developing an early cancer screening ecosystem through Cologuard, fostering strong physician loyalty. This funding structure chart (debt-to-equity) demonstrates leverage stability, where the indicator value reaches 1.06. Business growth relies on insurance standards and patient awareness, while profitability is regulated by government reimbursement limits for diagnostic ancillary services.

An analysis of the debt-to-equity ratio characterizes the financial stability of Exact Sciences (EXAS) within the oncology diagnostics sector. This coefficient compares total liabilities to net assets, determining the business's degree of dependence on external creditors. An increase in this metric signals a risk of balance sheet destabilization should revenue decline. For a company dependent on a single product, excessive debt is critical upon the emergence of cheaper alternatives. A low level of leverage guarantees survivability in the event of a reduction in insurance payouts.